S. Patton, M. Hall, and H. Ozen, Bladder cancer, Current Opinion in Oncology, vol.14, issue.3, pp.265-72, 2002.
DOI : 10.1097/00001622-200205000-00003

A. Alexandroff, A. Jackson, O. Donnell, M. , and J. K. , BCG immunotherapy of bladder cancer: 20 years on, The Lancet, vol.353, issue.9165, pp.1689-9410, 1999.
DOI : 10.1016/S0140-6736(98)07422-4

S. Brandau and H. Suttmann, Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement, Biomedicine & Pharmacotherapy, vol.61, issue.6, pp.299-305, 2007.
DOI : 10.1016/j.biopha.2007.05.004

D. Lamm, D. Riggs, C. Traynelis, and U. Nseyo, Apparent Failure of Current Intravesical Chemotherapy Prophylaxis to Influence the Long-Term Course of Superficial Transitional Cell Carcinoma of the Bladder, The Journal of Urology, vol.153, issue.5, pp.1444-5010, 1995.
DOI : 10.1016/S0022-5347(01)67427-5

M. Simons, O. Donnell, M. Griffith, and T. , Role of neutrophils in BCG immunotherapy for bladder cancer, Urologic Oncology: Seminars and Original Investigations, vol.26, issue.4, pp.341-346, 2008.
DOI : 10.1016/j.urolonc.2007.11.031

C. Ayari, H. Larue, H. Hovington, M. Decobert, F. Harel et al., Bladder Tumor Infiltrating Mature Dendritic Cells and Macrophages as Predictors of Response to Bacillus Calmette-Gu??rin Immunotherapy, European Urology, vol.55, issue.6, pp.1386-95, 2009.
DOI : 10.1016/j.eururo.2009.01.040

T. Chtanova, M. Schaeffer, S. Han, G. Van-dooren, M. Nollmann et al., Dynamics of Neutrophil Migration in Lymph Nodes during Infection, Immunity, vol.29, issue.3, pp.487-96, 2008.
DOI : 10.1016/j.immuni.2008.07.012

V. Brinkmann, U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann et al., Neutrophil Extracellular Traps Kill Bacteria, Science, vol.303, issue.5663, pp.1532-1537, 2004.
DOI : 10.1126/science.1092385

A. Cerwenka and L. Lanier, Ligands for natural killer cell receptors: redundancy or specificity, Immunological Reviews, vol.181, issue.1, pp.158-69, 2001.
DOI : 10.1034/j.1600-065X.2001.1810113.x

L. Zamai, C. Ponti, P. Mirandola, G. Gobbi, S. Papa et al., NK Cells and Cancer, The Journal of Immunology, vol.178, issue.7, pp.4011-617371953, 2007.
DOI : 10.4049/jimmunol.178.7.4011

J. Smith, Neutrophils, host defense and inflammation: a double-edged sword, J Leukoc Biol, vol.56, pp.672-867996043, 1994.

S. Michelson and J. Leith, Dormancy, Regression, and Recurrence: Towards a Unifying Theory of Tumor Growth Control, Journal of Theoretical Biology, vol.169, issue.4, pp.327-365, 1994.
DOI : 10.1006/jtbi.1994.1155

S. Bunimovich-mendrazitsky, E. Shochat, and L. Stone, Mathematical Model of BCG Immunotherapy in??Superficial Bladder Cancer, Bulletin of Mathematical Biology, vol.166, issue.6, pp.1847-7010, 2007.
DOI : 10.1007/s11538-007-9195-z

A. Jackson, A. Alexandroff, D. Fleming, S. Prescott, G. Chisholm et al., BACILLUS-CALMETTE-GUERIN (BCG) ORGANISMS DIRECTLY ALTER THE GROWTH OF BLADDER-TUMOR CELLS, International Journal of Oncology, vol.5, pp.697-70321559633, 1994.
DOI : 10.3892/ijo.5.3.697

K. Nepple, A. Lightfoot, H. Rosevear, O. Donnell, M. Lamm et al., Bacillus Calmette-Gu??rin With or Without Interferon ??-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer, The Journal of Urology, vol.184, issue.5, pp.1915-1924, 2010.
DOI : 10.1016/j.juro.2010.06.147

O. Donnell, M. Krohn, J. Dewolf, and W. , SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-??2B PLUS LOW DOSE BACILLUS CALMETTE-GUERIN IS EFFECTIVE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER IN WHOM BACILLUS CALMETTE-GUERIN ALONE PREVIOUSLY FAILED, The Journal of Urology, vol.166, issue.4, pp.1300-410, 2001.
DOI : 10.1016/S0022-5347(05)65757-6

D. Gillespie and L. Petzold, Improved leap-size selection for accelerated stochastic simulation, The Journal of Chemical Physics, vol.119, issue.16, p.8229, 2003.
DOI : 10.1063/1.1613254
URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.79.7666

M. Simons, K. Leidal, W. Nauseef, and T. Griffith, TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules, Journal of Leukocyte Biology, vol.83, issue.3, pp.621-630, 2008.
DOI : 10.1189/jlb.0707452

T. Griffith, T. Kucaba, O. Donnell, M. Burns, J. Benetatos et al., Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist, Apoptosis, vol.64, issue.1, pp.13-2610, 2011.
DOI : 10.1007/s10495-010-0535-3

A. Bisiaux, N. Thiounn, M. Timsit, A. Eladaoui, H. Chang et al., Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer, The Journal of Urology, vol.181, issue.4, pp.1571-80, 2009.
DOI : 10.1016/j.juro.2008.11.124
URL : https://hal.archives-ouvertes.fr/pasteur-01402294

S. Seow, J. Rahmat, B. Bay, Y. Lee, and R. Mahendran, Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette???Gu??rin or Lactobacillus rhamnosus strain GG in the healthy murine bladder, Immunology, vol.20, issue.3, pp.419-446, 2008.
DOI : 10.1016/S0168-1605(02)00045-4

V. Yutkin, D. Pode, E. Pikarsky, and O. Mandelboim, The Expression Level of Ligands for Natural Killer Cell Receptors Predicts Response to Bacillus Calmette-Guerin Therapy: A Pilot Study, The Journal of Urology, vol.178, issue.6, pp.2660-2664, 2007.
DOI : 10.1016/j.juro.2007.07.118

M. Saban, T. Sferra, C. Davis, C. Simpson, A. Allen et al., Neuropilin-VEGF signaling pathway acts as a key modulator of vascular, lymphatic, and inflammatory cell responses of the bladder to intravesical BCG treatment, AJP: Renal Physiology, vol.299, issue.6, pp.1245-56, 2010.
DOI : 10.1152/ajprenal.00352.2010

M. Saban, J. Backer, M. Backer, J. Maier, B. Fowler et al., VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation, AJP: Renal Physiology, vol.295, issue.1, pp.60-72, 2007.
DOI : 10.1152/ajprenal.00618.2007

C. Durek, E. Richter, A. Basteck, S. Rusch-gerdes, J. Gerdes et al., THE FATE OF BACILLUS CALMETTE-GUERIN AFTER INTRAVESICAL INSTILLATION, The Journal of Urology, vol.165, issue.5, pp.1765-810, 2001.
DOI : 10.1016/S0022-5347(05)66410-5

L. Kavoussi, E. Brown, J. Ritchey, and T. Ratliff, Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response., Journal of Clinical Investigation, vol.85, issue.1, pp.62-7240402910, 1990.
DOI : 10.1172/JCI114434
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC296387

R. Bevers, K. Kurth, and D. Schamhart, Role of urothelial cells in BCG immunotherapy for superficial bladder cancer, British Journal of Cancer, vol.86, pp.607-1215266312, 2004.
DOI : 10.1097/00005392-200008000-00078

P. Malmström, R. Sylvester, D. Crawford, M. Friedrich, S. Krege et al., An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Gu??rin for Non???Muscle-Invasive Bladder Cancer, European Urology, vol.56, issue.2, pp.247-56, 2009.
DOI : 10.1016/j.eururo.2009.04.038

J. Meyer, R. Persad, and D. Gillatt, Use of bacille Calmette-Guerin in superficial bladder cancer, Postgraduate Medical Journal, vol.78, issue.922, pp.449-54, 2002.
DOI : 10.1136/pmj.78.922.449

A. Morales, Intravesical Therapy of Bladder Cancer: An lmmunotherapy Success Story, International Journal of Urology, vol.147, issue.5, pp.329-362, 1996.
DOI : 10.1016/S0022-5347(01)67509-8

D. Lamm, D. Thor, S. Harris, J. Reyna, V. Stogdill et al., Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer, J Urol, vol.124, pp.38-406997513, 1980.

D. Boer, E. , D. Jong, W. Steerenberg, P. Aarden et al., Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Gu??rin in superficial bladder cancer, Cancer Immunology, Immunotherapy, vol.1, issue.5, pp.306-12154097710, 1007.
DOI : 10.1007/BF01741551

H. Suttmann, J. Riemensberger, G. Bentien, D. Schmaltz, M. Stockle et al., Neutrophil Granulocytes Are Required for Effective Bacillus Calmette-Guerin Immunotherapy of Bladder Cancer and Orchestrate Local Immune Responses, Cancer Research, vol.66, issue.16, pp.8250-8257, 2006.
DOI : 10.1158/0008-5472.CAN-06-1416

K. Taniguchi, S. Koga, M. Nishikido, S. Yamashita, T. Sakuragi et al., Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for superficial bladder cancer, Clinical and Experimental Immunology, vol.157, issue.1, pp.131-136, 1999.
DOI : 10.1097/00005392-199602000-00016

A. Jackson, A. Alexandroff, R. Kelly, A. Skibinska, K. Esuvaranathan et al., Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Gu??rin (BCG) immunotherapy, Clinical & Experimental Immunology, vol.11, issue.3, pp.369-757882559, 1995.
DOI : 10.1111/j.1365-2249.1995.tb05560.x

S. Siracusano, F. Vita, R. Abbate, S. Ciciliato, V. Borelli et al., The Role of Granulocytes Following Intravesical BCG Prophylaxis, European Urology, vol.51, issue.6, pp.1589-97, 2007.
DOI : 10.1016/j.eururo.2006.11.045

R. Clark and S. Klebanoff, Neutrophil-mediated tumor cell cytotoxicity: role of the peroxidase system, Journal of Experimental Medicine, vol.141, issue.6, pp.1442-1449, 1975.
DOI : 10.1084/jem.141.6.1442

H. Rosevear, A. Lightfoot, O. Donnell, M. Griffith, and T. , The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette???Gu??rin (BCG) immunotherapy for urothelial carcinoma of the bladder, Cancer and Metastasis Reviews, vol.66, issue.Suppl 3, pp.345-53, 2009.
DOI : 10.1007/s10555-009-9195-6